technology offerings: 2013 bio international convention

Johns hopkins technology offerings

fast facts

Johns hopkins Technology Transfer 2013 Bio inTernaTional convenTion

Johns hopkins technology transfer 2 Johns hopkins technology transfer 2

cancer: personalized Medicine k.o.l.

ronald Berger, M.d., ph.d.

BoB Bollinger, M.d., M.p.h.

ivan Borrello, M.d.

paul BoTToMley, ph.d.

Jay BreaM, ph.d.

irina Burd, M.d., ph.d.

luis alBerTo diaz, Jr., M.d.

luis andres garza, M.d., ph.d.

zachary kaMinsky, ph.d.

Jin kang, ph.d.

isaac kinde

Marikki laiho, M.d., ph.d.

tABle of contents

4

6

7

8

9

10

11

12

13

14

15

16

17

inventor fact sheets3 inventor fact sheets3

richard MarkhaM, M.d.

susuMu Mori, ph.d.

hien nguyen, M.d., facs

Jeffrey roThsTein, M.d., ph.d.

Jeffrey siewerdsen, ph.d.

BarBara slusher, ph.d.

saraswaTi sukuMar, ph.d.

elaine Tierney, M.d.

peTer van ziJl, ph.d.

richard wahl, M.d., facr

clifford weiss, M.d.

williaM wong, ph.d.

srinivasan yegnasuBraManian, M.d., ph.d.

18

19

20

21

22

23

24

25

26

27

28

29

30

Bert Vogelstein, M.D.Clayton Professor of Oncology and PathologyInvestigator, Howard Hughes Medical InstituteDirector, Ludwig Center for Cancer Genetics and TherapeuticsSidney Kimmel Comprehensive Cancer Center

Research InterestsDr. Vogelstein’s laboratory has identified a series of genetic alterations which, in concert, convert a normal epithelial cell to a malignant one. These genetic alterations affect a specific subset of oncogenes and tumor suppressor genes. The goals of Dr. Vogelstein’s current research include the following:

• Identification of other genes which, when mutated, contribute to human tumorigenesis.

• Delineation of the pathways through which these genes act.• Development of targeted therapies based on this knowledge.• Development of new diagnostic approaches based on the genes

responsible for neoplasia.

Johns hopkins technology transfer 4

cAncer: personAliZeD MeDicine, k.o.l.

Kenneth Kinzler, Ph.D.Professor of OncologyDirector, Ludwig Center for Cancer Genetics and TherapeuticsSidney Kimmel Comprehensive Cancer Center

Research InterestsDr. Kinzler’s laboratory has focused on the genetics of human cancer. They have identified a variety of genetic mutations that underlie cancer, including mutations of the APC pathway that appear to initiate the majority of colorectal cancers and IDH1/2 mutations that underlying many gliomas. In addition, they have developed a variety of powerful tools for analysis of expression and genetic alterations in cancer. Most recently, they have pioneered integrated whole genome analyses of human cancers through expression, copy number, and mutational analyses of all the coding genes in several human cancer types including colorectal, breast, pancreatic and brain. The identification of genetic differences between normal and tumor tissues provide new therapeutic targets, new opportunities for the early diagnosis of cancer, and important insights into the neoplastic process.

inventor fact sheets5

Technology PortfoliosMethods and Biomarkers for the Detection and Diagnosis of pancreatic neuroendrocrine tumors and pancreatic cysts

• C11331: Methods and Biomarkers for the Detection of Pancreatic Neuroendrocrine Tumors

• C11545: Novel Molecular Diagnostic for Pancreatic Cystic Lesions• C11616: Digital Ligation for the Detection of Rare Genetic Variants• C11769: Novel Biomarker for Diagnosis of Pancreatic Cysts

Biomarkers for the Detection and Diagnosis of Medulloblastoma and Brain cancer

• C11276: Biomarkers for the Detection and Diagnosis of Medulloblastoma

• C11618: Novel Molecular Diagnostic for Aggressive Brain Tumors• C11619: Novel Molecular Diagnostic for Brain Cancer

licensing AssociAte

Keith Baker Senior Director, LicensingPhone: 410-516-4563 Email: [email protected]

Nickolas Papadopoulos, Ph.D.Associate Professor of Oncology Director of Translational Genetics, Ludwig Center for Cancer Genetics and Therapeutics Sidney Kimmel Comprehensive Cancer Center

Research InterestsDr. Papadopoulos is working to identify the genetic changes underlying the development of pancreatic neuroendocrine tumors. Dr. Papadopoulos’ current focus is on cancer genomics. He was part of the interdisciplinary team that was first to sequence all of the protein coding genes and determine genetic alterations and construct expression profiles in multiple tumors of four different common human cancers. Recent efforts involved the identification of genetic alterations that drive tumorigenesis using a new generation of sequencing technologies. He has developed an in-house sequencing pipeline based on massively parallel sequencing. He discovered the identification of novel, signature mutations in ovarian clear cell carcinomas and pancreatic neuroendocrine tumors. Dr. Papadopoulos’ most recent efforts focus on the translation of the information derived from genomic studies to diagnostics, especially early detection.

http://tinyurl.com/JHUC11331









http://www.jhttonline.jhu.edu/TechnologyDetail.aspx%3FTechID%3DE67156A0-455E-4388-8F84-8444407F874A%26JHURef%3DC11619

Johns hopkins technology transfer inventor fact sheets6 7

Ronald Berger, M.D., Ph.D.Professor of Medicine and Biomedical EngineeringCardiac Electrophysiology Training Program Director

BiographyRonald D. Berger, M.D., Ph.D., received his B.S., M.S., and Ph.D. degrees in Electrical Engineering from M.I.T. in 1981, 1983, and 1987, respectively, and his M.D. degree from Harvard Medical School in 1987. He completed residency training in internal medicine at the Brigham and Women’s Hospital and fellowship training in cardiology and cardiac electrophysiology at Johns Hopkins before joining the cardiology faculty at Hopkins in 1993. He was promoted to professor of medicine and biomedical engineering at Johns Hopkins in 2005, and is director of the training program in cardiac electrophysiology there.

Dr. Berger has published more than 200 papers in peer-reviewed medical journals and holds more than 20 patents in the fields of arrhythmia detection, catheter ablation, defibrillation, and cardiopulmonary resuscitation. He is the recipient of distinguished honors including a FIRST Award from the National Institutes of Health and an Established Investigator Award from the American Heart Association. Dr. Berger is a cofounder of three medical device companies and has served on the advisory boards for 8 eight others. His academic focus is on arrhythmia device technology, signal processing, and technology transfer.

Research InterestsDr. Berger and his team have worked to demonstrate that application of a high-frequency AC field can be used to successfully and reversibly treat cardiac arrhythmias.

Technology Portfolio• C10996: Method for Determining Ventricular Arrhythmia Risk

Based on Analysis of ECG Recording• C10844: Gentler Method for Termination of Cardiac

Arrhythmias• C04301: Easy Catheter Ablation of Atrial Tissue• C03941: System For Refibrillation of the Heart For Treatment

of Post Countershock Pulseless Electrical Activity and Asystole

• C03552: Cardiac Sock Electrode and Implantable Defibrillator System

licensing AssociAteHeather BakalyarPortfolio DirectorPhone: 410-516-6653Email: [email protected]












licensing AssociAteMontserrat Capdevila Director, Marketing, Sales, and International RelationsPhone: 410-516-6654Email: [email protected]

BiographyRobert C. Bollinger, M.D., M.P.H., is a professor of infectious diseases in the department of medicine at The Johns Hopkins University School of Medicine, with joint appointments in the department of international health at The Johns Hopkins Bloomberg School of Public Health and The Johns Hopkins School of Nursing. He has more than 30 years of experience in international public health, clinical research and education in a broad range of global health priorities.

Dr. Bollinger is also the country director for the Hopkins Fogarty International Programs in India, which has provided short-term and degree training to more than 100 visiting scientists at Hopkins, as well as in-country training for more than 2,000 scientists since 1992.

Dr. Bollinger is the director of the Hopkins Center for Clinical Global Health Education (CCGHE) which develops and provides clinical education to health care providers in resource-limited settings around the world. Under Dr. Bollinger’s leadership, the CCGHE has developed educational and research programs in 18 countries and been a leader in the development and use of distance learning and mHealth technology in resource-limited settings.

Research InterestsDr. Bollinger’s research interests include the identification of biological and behavioral risk factors for HIV transmission and the characterization of clinical progression and treatment of HIV infection and related infections. He is also engaged in implementation science research projects focused on optimizing strategies to improve health care capacity and care delivery in resource-limited settings through task-shifting, clinical education, distance learning, and mHealth.

Technology Portfolio• C12031: eMOCHA Solutions: A New Smart mHealth Platform

Bob Bollinger, M.D., M.P.H.Director, Johns Hopkins Center for Clinical Global Health Education (CCGHE)Associate Director, Johns Hopkins Center for Global Health


BiographyIvan Borrello, M.D., is an associate professor of oncology at The Johns Hopkins University School of Medicine and practices at the Sidney Kimmel Comprehensive Cancer Center. His expertise is in bone marrow transplants, hematologic malignancies, immunotherapy, and multiple myeloma. Dr. Borrello earned his medical degree at the Medical College of Virginia School of Medicine. He completed his residency at the University of Chicago and his fellowship at Johns Hopkins Hospital.

Research InterestsDr. Borrello’s clinical interests focus in multiple myeloma and his research interests consist of developing immune-based strategies for the treatment of myeloma. His research focuses on two major aspects: 1) developing novel approaches to adoptive T cell therapy and 2) overcoming mechanisms of immune suppression. The T cell approach focuses on marrow infiltrating lymphocytes (MILs). Dr. Borrello has shown these cells to possess greater anti-tumor efficacy than blood T cells as well as other traits that make them more ideal for therapeutic use. This work led to the development of a clinical infrastructure to grow the cells and the development of clinical trials including a randomized Phase 2 study for high-risk myeloma. Additional applications of MILs have been in the allogeneic transplant setting where his lab has shown that expansion of these cells from the patients (and not the donors) can impart highly specific anti-leukemia benefits with clinical studies to start in the next year. In terms of immunosuppressive approaches, his group made the observation that commonly used PDE5 inhibitors such as Viagra and Cialis can be effectively and safely used to inhibit the immunosuppression generated by myeloid derived suppressor cells (M.D.SCs). The clinical results from the first study confirm the preclinical observations that these drugs can modulate immune function. Additional clinical trials are currently underway to examine the anti-tumor efficacy of these drugs in multiple myeloma and head and neck cancer.

Technology Portfolio• C04580: PDE Inhibitors in Immunotherapy• C10428: Cellular Therapy for Hematological Malignancies• C12054: A Safer and More Effective T Cell Cancer

Immunotherapy

licensing AssociAtePauline CallinanSenior Licensing AssociatePhone: 410-516-5496Email: [email protected]

Ivan Borrello, M.D. Associate Professor of OncologyMedical Director of the Johns Hopkins Cell Therapy Lab






BiographyPaul A. Bottomley, Ph.D., received his Ph.D. in physics in 1978 from the University of Nottingham, UK. There, he was a member of the first original team to developed the first human MRI scanner. He was a research associate at The Johns Hopkins University from 1978–1980 and a physicist at GE Research and Development Center from 1980–1994. He is currently a Russell H. Morgan Professor and director of the division of MR research of the Russell H. Morgan Department of Radiology and Radiological Sciences and The Johns Hopkins University. He is the recipient of several awards, including the gold medal of the Society of Magnetic Resonance in Medicine, 1989; Coolidge Fellowship and Medal, GE Company, 1990; gold, silver, and bronze patent medals, GE Company.

He developed the original techniques for performing localized nuclear magnetic resonance (NMR) spectroscopy, and has ongoing clinical research studies employing phosphorus (31P) to study energy metabolism in humans. His research specialties include in vivo NMR, MRI, tissue relaxation times, localized NMR spectroscopy, human cardiac NMR spectroscopy, interventional MRI, and MRI safety.

Research InterestsDr. Bottomley’s lab is working to optimize of surface MRI detectors to maximize the SNR, including the development of new strip-detectors, as well as tiny catheter-based MRI detectors for internal/intravascular use, and “MRI endoscopy.” Of central interest at the moment—following development with Dr. Clifford Weiss in Cardiology of a method to measure metabolic flux—is the observation of a shortfall in energy supply in patients with heart failure.

Technology Portfolio• C11466: One-Step MRI Method to Increase Image Contrast • C11463: Real-Time High Dynamic Range RF Power Monitor• C11462: Novel Method of Performing Localized Magnetic

Resonance Spectroscopy• C09885: Methods & Applications of Rapid Magnetic

Resonance Sensitive to Longitudinal Relaxation Times

• C04541: Multi-turn Element RF Coil Array for Multiple Channel MRI• C03771: Practical Tunable Planar and Cylindrical Multi-element Magnetic

Resonance Detector Arrays

Paul Bottomley, Ph.D.Russell H. Morgan Professor, Department of RadiologyDirector, Division of Magnetic Resonance Research

licensing AssociAteAmi GadhiaPortfolio Director Phone: 410-516-6515 Email: [email protected]













Jay Bream, Ph.D.Associate Professor, Department of Molecular Microbiology and ImmunologyCo-Director, The Becton Dickinson Immune Function LaboratoryThe Johns Hopkins Bloomberg School of Public HealthGraduate Program in ImmunologyThe Johns Hopkins University School of Medicine

BiographyJay Bream, Ph.D., received is Ph.D. from The Pennsylvania State University in 1996 in biobehavioral health. After completing his Ph.D., Dr. Bream was a postdoctoral fellow in the laboratory of experimental immunology, cellular and molecular immunology section at the National Cancer Institute. Dr. Bream then became a research fellow in the molecular immunology and inflammation branch at the National Institute of Arthritis, Musculoskeletal and Skin Diseases. Dr. Bream was recruited to The Johns Hopkins Bloomberg School of Public Health in 2004 to bolster translational research in human immunology at the school. Part of this effort included the establishment of The Becton Dickinson Immune Function Laboratory as a means to promote interdisciplinary research in immunology.

Research InterestsDr. Bream’s research is aimed at bridging the gap between genetic polymorphism and biological function. His work specifically addresses the basic mechanisms of IL-10 gene expression and the application of these data to allelic variation. To investigate cell type-specific human IL-10 regulation, he created a human IL-10 transgenic mouse with a bacterial artificial chromosome (hIL10BAC). He examined the in vivo function of cell-specific human IL-10 expression by reconstituting Il10-/- mice with the transgene (Il10-/-/hIL10BAC). He has found that in response to endotoxin challenge, Il10-/-/hIL10BAC mice regulate IL-10-target genes and normalize sensitivity to LPS toxicity via faithful human IL-10 expression from myeloid cells.

Other goals of his research program include: (1) elucidating the molecular mechanisms of cell- and signal-specific IL-10 gene regulation, (2) determine how human cell type-specific human IL-10 regulation impacts disease outcomes, and (3) utilize functional genomics to investigate the translation of genetics and disease association data into a mechanistic and functional immunologic context.

Technology Portfolio • C12089: Humanized Transgenic Mouse Model of IL-10

licensing AssociAteRachel CassidyPortfolio DirectorPhone: 410-516-4562Email: [email protected]



BiographyIrina Burd, M.D., Ph.D., was recruited to The Johns Hopkins University to spearhead the development of the field of fetal medicine and fetal neurology, and is the founder of The Johns Hopkins Integrated Research Center for Fetal Medicine. Dr. Burd earned her bachelor of arts degree from Rutgers University (Summa Cum Laude) and completed the M.D./Ph.D. program at The University of Medicine and Dentistry – Robert Wood Johnson Medical School. She completed her residency in Obstetrics and Gynecology at The Thomas Jefferson University and her fellowship in Maternal Fetal Medicine at The University of Pennsylvania.

Dr. Burd is the recipient of numerous honors, including the Ikaria Research Award from the Perinatal Research Society, a research award from the American Board of Obstetrics and Gynecology/American Association of Gynecology and Obstetrics Foundation (ABOG/AAOGF), the Thomas Bogg’s Award from the Philadelphia Perinatal Society and Passano Foundation Clinician Scientist Award. She is a recipient of NIH Award to study the role of IL1β receptor in perinatal brain injury.

Research InterestsDr. Burd developed a research program studying the pathogenesis of fetal brain injury with exposure to intrauterine inflammation. She studies biomarkers of prenatal brain injury and neuroprotective agents that could be used in utero to prevent cerebral palsy.

Technology Portfolio• C12048: Diagnostic ELISA Assay for Perinatal Brain Injury• C12023: Autologous Adult Stem Cell Therapy for Prevention

of Pre-Term Birth• C11801: Cerebral Palsy: An In Utero Biomarker

Irina Burd, M.D., Ph.D.Assistant Professor of Gyn/OB and NeurologyDirector of Research, Division of Maternal Fetal MedicineDepartment of Gynecology and Obstetrics

licensing AssociAteLaura MitchellLicensing AssociatePhone: 410-516-4969Email: [email protected]





Luis Alberto Diaz, Jr., M.D.Associate Professor of OncologyDirector of Translational Medicine Ludwig Center for Cancer Genetics and Therapeutics

BiographyLuis Diaz, M.D., is director of translational medicine at the Ludwig Center for Cancer Genetics and Therapeutics at The Johns Hopkins Kimmel Cancer Center. Dr. Diaz is also director of a new clinic for patients with metastatic colorectal cancer. This clinic focuses on the treatment of all aspects related to these patients, including support with pain, nutrition, psycho-social issues, and access to clinical trials and cutting-edge therapies. Dr. Diaz is also the chief medical officer and cofounder of Personal Genome Diagnostics.

Dr. Diaz received his medical degree from the University of Michigan Medical School, and completed his general medicine training at Johns Hopkins followed by a fellowship in medical oncology at The Johns Hopkins Kimmel Cancer Center.

Research InterestsDr. Diaz’s clinical interests include gastrointestinal cancers including colorectal cancer and pancreatic cancer. The focus of Dr. Diaz’s research is two-fold. The first is translating novel and often high-risk therapeutics with unique mechanisms of action from the lab to patients. One example is using live bacteria to target and destroy solid tumors. This approach, termed bacteriolytic therapy, is being testing in clinical trials at Johns Hopkins and the University of Pennsylvania in humans and canines with advanced solid tumors. His second area of research includes a novel test that measures tumor-derived DNA in the bloodstream. The blood test, based on the unique genetic fingerprint contained within the genome of every cancer, can detect the presence of tumor and track its progress. The ultimate goal of this work being early detection of cancer with a simple blood test before it becomes lethal.

Technology Portfolio• C12191: PapGene Test• C11618: Novel Molecular Diagnostic for Aggressive Brain

Tumors• C11545: Novel Molecular Diagnostic for Pancreatic Cystic

Lesions• C11331: Methods and Biomarkers for the Detection of

Pancreatic Neuroendrocrine Tumors• C11229: Enhanced Delivery of Nanoparticles to Tumors• C10690: Methyl-BEAMing: Digital Quantification of DNA

Methylation

licensing AssociAteKeith Baker Senior Director, LicensingPhone: 410-516-4563 Email: [email protected]












BiographyLuis Garza, M.D., Ph.D., is the assistant professor of dermatology at the The Johns Hopkins University School of Medicine where he practices both general dermatology and specialized wound care. In addition to treating patients, he runs a molecular biology laboratory, which studies skin stem cells and wound healing with an emphasis on identifying the next generation of wound therapeutics and diagnostics. Dr. Garza earned his medical and graduate degrees at The University of Pennsylvania School of Medicine. He completed a residency in dermatology at The University of Michigan, and a fellowship in skin stem cells at The University of Pennsylvania.

Research InterestsDr. Garza’s lab is interested in investigating hypotheses on basic skin questions that are directly relevant to skin disease in humans. The lab looks to answer basic questions regarding stem cell biology and regeneration, The current focus of the lab is on how prostaglandins influence wound healing and regeneration in the context of hair cycling. For example, what role do prostaglandins play in the de novo regeneration of a full hair follicle after wounding in adult mice (Ito et al., 2007)? Understanding these questions will have broad significance to regeneration and stem cell biology in multiple organs. Understanding wound healing programs that re-initiate embryonic developmental patterns might eventually lead to insights on how to trigger the regrowth of a severed human limb, for example.

Technology Portfolio• C11828: A Method to Change Skin Identity at Amputation

Sites• C11708: Therapeutic Targets for Hair Growth and Wound

Healing• C11534: A Minimally Invasive Skin Biopsy Device for

Removal of Skin Conditions in the Epidermis• C11509: Therapeutic Targets to Enhance and Inhibit Hair

Growth

Luis Andres Garza, M.D., Ph.D.Assistant ProfessorDepartment of Dermatology The Johns Hopkins University School of Medicine


licensing AssociAteAditi MartinLicensing AssociatePhone: 410-516-4566 Email: [email protected]










Zachary Kaminsky, Ph.D.Assistant Professor, Department of Psychiatry and Behavioral Sciences

Research InterestsZachary Kaminsky, Ph.D., is trying to identify epigenetic factors underlying psychiatric disease with a particular focus on mood disorders. His lab employs genome wide exploratory analyses using microarrays to identify disease associations in humans or animal models of various conditions including major depression, postpartum depression, and suicide.

A major thrust of Dr. Kaminksy’s work is to reduce confounders and allow for the cell type specific analysis of epigenetic patterns in the brain. To this end his laboratory has generated a bioinformatic method capable of quantifying and normalizing for cellular heterogeneity based on DNA methylation marks, utilizing data from fluorescence activated sorting (FACS) derived neuronal and glial DNA methylation profiles.

A second focus of Dr. Kaminksy’s work is the development of disease risk predictive biomarkers utilizing DNA methylation marks in peripheral tissues. His research team is currently in the process of developing biomarkers predictive of postpartum depression and suicide risk.

Technology Portfolio• C12094: Biomarkers for Predicting Postpartum Depression

Risk





BiographyJin U. Kang, Ph.D., is a professor and Chair of the Electrical and Computer Engineering Department at The Johns Hopkins University. He earned a BS in physics from Western Washington University, and both MS and Ph.D. degrees from the School of Optics (CREOL) at The University of Central Florida. Prior to joining Johns Hopkins, he was a research scientist with the U. S. Naval Research Laboratory in Washington DC. He has developed various fiber sources from single longitudinal mode tunable lasers to mode-locked femtosecond lasers. He was also the first to experimentally demonstrate the existence of several important novel effects and devices including Manakov Spatial Solitons and backward propagating second harmonic generation. He has published more than 100 journal papers and 150 conference publications.

Research InterestsDr. Kang’s research is focused on developing novel fiber optic devices and systems for various applications in medical, communications, and sensors. He conducts experimental/theoretical investigations in the area of photonics and optoelectronics with emphasis on developing novel fiber laser systems and ultrafast optoelectronic devices for applications in military, communications, sensors, and space sciences.

Technology Portfolio• C11649: A Real-Time Noise Subtraction for FD-OCT using

the GPU• C11485: New Methods for Intraocular Laser Therapy Using

Quantum Cascade Laser (QCL)• C11396: Fiber-Optic Confocal Microscope that Compensates for

Breathing and Blood Flow• C11386: Fiber Bundle Based Endoscopic Microscope System• C11378: OCT-Based 4D View for Micro-Surgery Procedures• C11377: A Novel Graphics Processing Unit (GPU) that Up-Grades the

Signal for FD-OCT• C11324: Full-range Complex-conjugate-free Endoscopic Spectral-

domain Optical Coherence Tomography• C11161: 1-D Surface Tracking and Motion Compensation Hand-held

Microsurgical Tool System Based on Dynamic Common-Path Optical Coherence Tomography Sensor

Jin Kang, Ph.D.Professor and Department ChairElectrical and Computer Engineering

licensing AssociAteNestor FrancoLicensing AssociatePhone: 410-516-5654Email: [email protected]
















BiographyIsaac Kinde is a M.D. and Ph.D. candidate at The Johns Hopkins University School of Medicine. He is working under the expert guidance of Luis Diaz, M.D.; Nickolas Papadopoulos, Ph.D.; Kenneth Kinzler, Ph.D.; and Bert Vogelstein, M.D. In 2012 he was named one of Forbes’ Magazine’s 30 Under 30 Rising Stars in Healthcare. Recently his work with the Luis Diaz, M.D. on the PapGene Test (JHU Invention C12191) was referenced in the New York Times and the Baltimore Sun and he was interviewed by USA Today for a featured story. Mr. Kinde will also keynote the 2013 BIO International Convention in Chicago, IL.

Research InterestsMr. Kinde is developing techniques to improve the accuracy of DNA sequencing technology and demonstrating that it might be used to detect cancers arising from the colon, pancreas, and ovaries in a simple, noninvasive manner. Already, several patents have been applied for and he’s been published in Science Translational Medicine, Nature, and other journals.

Technology Portfolio• C12191: PapGene Test• C11953: Rapid Genome Sequencing Method for Prenatal

Diagnosis• C11475: Novel Diagnostic Tool for Rare Disorders

Isaac KindeM.D., Ph.D. Candidate The Johns Hopkins University School of Medicine

licensing AssociAteKeith Baker Senior Director, LicensingPhone: 410-516-4563 Email: [email protected]






Marikki Laiho, M.D., Ph.D.Willard and Lillian Hackerman Professor in Radiation OncologyProfessor of Radiation Oncology and OncologySidney Kimmel Comprehensive Cancer Center

BiographyMarikki Laiho, M.D., Ph.D., is a Willard and Lillian Hackerman Professor in Radiation Oncology and professor of radiation oncology and oncology at The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Dr. Laiho has long-standing, recognized experience in cancer biology in the fields of tumor suppressor research and DNA damage biology. She has led externally funded academic research projects for the past 20 years, built multidisciplinary research teams and mentored more than 40 undergraduate and graduate students and postdoctoral fellows. She has received several research awards and acts as an expert for numerous international research agencies. She has coordinated international research networks, established a state-of-the-art cellular imaging unit and directed cancer research programs at The University of Helsinki, Finland and currently at The Johns Hopkins University School of Medicine. She is the director of a division that focuses on the basic mechanistic aspects of cellular responses to genetic lesions and strives towards translating this information to improved cancer therapies. She has established a comprehensive research team and built collaborations to increase their translational focus. She is director of division of molecular radiation sciences and codirector of a cancer center developmental program on DNA damage biology.

Research InterestsDr. Laiho’s research studies the relevance and implications of cellular DNA damage response in cancer. Her laboratory strives to understand the relevance of the damage response at the cellular and organ level, and to define differences that exist between cancer and normal cells. Her laboratory has made several seminal findings on the regulation of p53 tumor suppressor protein in DNA damage, and has applied these to discovery screens of lead therapeutic molecules. Her goal is to dissect the mechanisms of action of these novel small-molecule lead compounds in cancer.

Technology Portfolio• C12379: RNA Polymerase I Inhibitors to Treat Cancers

licensing AssociAteJeffrey JamesLicensing AssociatePhone: 410-516-4560Email: [email protected]




Research InterestsRichard Markham, M.D., and his lab are pursuing three lines of investigation in the area of HIV-1 pathogenesis and prevention.

1. Viral genetic evolution. These studies have been undertaken on the premise that longitudinal analysis of the genetic evolution of HIV-1 will provide insights into host-virus interactions that cannot be readily determined by direct examination of host factors. These types of studies have revealed qualitative differences in the host-virus interaction between individuals with rapidly and slowly progressive disease and suggest strategies that might be employed for eradicating virus from infected individuals with greatly reduced viral loads.

2. Sexual transmission of HIV-1 using infected cells. Dr. Markham’s lab developed a mouse model of vaginal transmission of HIV-1 using infected cells. Using the model, the lab examines different strategies that might interrupt this route of transmission.

3. Development of candidate HIV-1 vaccines. The lab is examining the immunogenicity and protective efficacy of synthesized virus-like particles containing pro-viral DNA encoding specific HIV genes and coated with polypeptides designed to mimic the potential envelope three dimensional structures that would result from the full range of mutations that could occur within a highly immunogenic region of the envelope gene.

Technology Portfolio• C11041: Novel Immunotherapeutic approach to Prevent HIV-

1 Transmission• C04854: Antibody Based Anti-HIV-1 Microbicide Targeting a

Host Protein• C01443: Compositions and Methods for Prevention of HIV

Transmission Across Mucosal Surfaces

Richard Markham, M.D.Professor, Department of Molecular Microbiology and ImmunologyThe Johns Hopkins Bloomberg School of Public Health

licensing AssociAteRachel CassidyPortfolio DirectorPhone: 410-516-4562Email: [email protected]









Susumu Mori, Ph.D.Professor, Department of RadiologyDirector, Center for Brain Imaging Science

BiographyFrom 1991 - 1996, Susumu Mori, Ph.D., worked on his Ph.D. in Biophysics at The Johns Hopkins University School of Medicine under the supervision of Dr. Peter van Zijl. He then did a postdoctoral fellowship in the department of radiology at Johns Hopkins, becoming an assistant professor in radiology at The Johns Hopkins University School of Medicine in 1997. He became an associate professor at Johns Hopkins in 2002, and a professor in 2006. He has received several awards for his work, including the 2001 Young Investigator’s Award from the Human Frontier Science Foundation, the 1996 Martin and Carol Macht Research Prize, from Johns Hopkins University, and the 1994 Rabi Award from the International Society of Magnetic Resonance in Medicine

Research InterestsDr. Mori is developing new data acquisition and analysis technologies of magnetic resonance imaging to study the brain anatomy. Diffusion tensor imaging and microimaging techniques have been the main focus of the technology development. The new techniques have been applied to various types of brain research including normal brain development and aging as well as diagnosis of brain diseases including Alzheimer’s disease, Huntington’s disease, and developmental disorders. The technologies have also been applied to high-resolution imaging of developing mouse brains and phenotype characterization. His lab is currently working on automated MR image analysis.

Technology Portfolio• C03471: Fiber Reconstruction Method using Data Acquired

by Magnetic Resonance Imaging

licensing AssociAteAmi GadhiaPortfolio DirectorPhone: 410-516-6515 Email: [email protected]




BiographyHien Nguyen, M.D., FACS, is the director of the Johns Hopkins Comprehensive Hernia Center, an assistant professor of surgery in The Johns Hopkins University School of Medicine and an associate medical director for the Center for Bioengineering Innovation and Design (CBID) in The Johns Hopkins Whiting School of Engineering. He earned his medical degree at The University of California Davis School of Medicine. He completed training in general surgery at The University of California San Francisco East Bay, followed by a fellowship in advanced laparoscopic and bariatric surgery at The Johns Hopkins University School of Medicine. Board-certified in general surgery, Dr. Nguyen is an expert in single-incision surgery, robotic surgery and laparoscopic bariatric surgery (which includes Roux-en-Y gastric bypass, adjustable gastric bands, sleeve gastrectomy and duodenal switch). He was instrumental in helping to establish the single-incision approach for laparoscopic surgery at The Johns Hopkins Medical Institutions.

Research InterestsDr. Nguyen research interests include clinical outcomes in hernia surgery, critical care medicine, bariatric surgery and metabolic syndrome. He specializes in minimally invasive surgery and his surgical practice involves the repair of complex hernias, abdominal wall reconstruction, as well as bariatric surgery. His FastStitch device has won many accolades, including a grant from the National Collegiate Inventors and Innovators Alliance, an award from the Abell Foundation at the 2012 Annual Joint Meeting of the Johns Hopkins Alliance for Science and Technology Development and the University of Maryland, Baltimore Commercial Advisory Board, and finished first place in business competitions at the University of Maryland, University of California, Irvine and the ASME Innovation Showcase.

Technology Portfolio• C11888: FastStitch: The Future of Suture• C11660: Keystone Precision Surgical Instruments: An

Innovation in Design and Performance• C11623: Time-saving Laparoscopic Lens Cleaning Tool

Hien Nguyen, M.D., FACSDirector, Comprehensive Hernia CenterAssistant Professor of Surgery, School of MedicineAssociate Medical Director, Center for Bioengineering Innovation and Design (CBID), Whiting School of Engineering

licensing AssociAte

Nestor FrancoLicensing AssociatePhone: 410-516-5654Email: [email protected]






Jeffrey Rothstein, M.D., Ph.D. The John W. Griffin, M.D., Director, Brain Science InstituteProfessor of Neurology and NeuroscienceDirector, Robert Packard Center for ALS Research

BiographyJeffrey D. Rothstein, M.D., Ph.D., is the director of the Brain Science Institute, professor of neurology and neuroscience and deputy director of The Johns Hopkins Institute for Clinical Translation. He is a faculty member of the Graduate Program in Cellular and Molecular Medicine at Johns Hopkins University. He is the founder and director of the Robert Packard Center for ALS Research at Johns Hopkins, the largest academic organization dedicated towards understanding ALS and developing novel therapeutics, and the director of the M.D.A/ALS Clinic, one of the largest ALS clinics in the USA. Dr. Rothstein has been the principal and/or local investigator in almost a dozen National or International trials in ALS.

Research InterestsDr. Rothstein’s clinical specialization is in neuromuscular disease, with a particular focus on amyotrophic lateral sclerosis. Other clinical areas relevant to his laboratory-based research include: epilepsy and spinocerebellar ataxia, and brain tumors. His work on glutamate transporters and astroglial dysfunction was the first evidence that glial dysfunction could contribute and accelerate neurodegenerative disease. More recently he has discovered a new role for oligodendroglia in supporting neurons and in ALS pathogenesis. His group has generated the largest library of ALS induced pluripotent cells for ALS research. His lab has spent the last 15 years using pathogenic cascade to discover new ALS therapeutics.

Brain Science InstituteThe Johns Hopkins University School of Medicine’s Brain Science Institute (BSi) brings together approximately 450 basic and clinical neuroscientists from across the Johns Hopkins campuses. BSi’s mission is to solve fundamental questions about brain development and function and to use these insights to understand the mechanisms of brain disease. The goals of BSi’s research are to foster new programs in basic neuroscience discovery, initiate a translational research program that will develop new treatments for brain-based diseases and encourage collaboration, interdisciplinary teams, and new thinking that will have a global influence on research and treatment of the nervous system. BSi’s specific research focuses on neurogenetics, new approaches to perception and cognition, pain, regeneration and repair in the nervous system, schizophrenia, neurodegeneration such as ALS and Alzheimer’s and autism. To translate Johns Hopkins Neuroscience discovery to real therapeutics, the BSi Neurotranslational program, comprised on more than 25 medicinal chemists, assay biologists and specialists in animal models, with decades of experience in the pharmaceutical industry, has effectively developed novel small molecule therapeutics for diverse disease including schizophrenia, chronic pain and brain tumors.

licensing AssociAte

Heather BakalyarPortfolio DirectorPhone: 410-516-6653 Email: [email protected]



BiographyJeff Siewerdsen, Ph.D., founded the I-STAR Lab as a collaborative endeavor among technical disciplines (engineering and physics) and clinical disciplines (radiology, surgery, and radiation therapy). He is primary faculty in biomedical engineering and the principal investigator on topics of image quality and cone-beam CT applications in diagnostic and image-guided procedures. He leads a program of interdisciplinary research spanning projects in medical imaging physics, diagnostic radiology, and image-guided interventions.

Research InterestsDr. Siewerdsen’s research involves the development of new imaging technologies and the translation of new imaging methods to diagnostic and image-guided procedures. His emphasis is in advanced x-ray imaging techniques, including cone-beam CT, tomosynthesis, and dual-energy imaging. Dr. Siewerdsen’s laboratory has offered numerous advances in the field of medical imaging, including the development of cone-beam CT for image-guided radiation therapy and surgery; the design and implementation of systems for ORs of the future; and the development of high-performance dual-energy x-ray imaging techniques for diagnostic and image-guided procedures. His research program fosters a highly collaborative, multi-disciplinary environment of medical physicists, engineers, computer scientists, radiologists, radiation oncologists, and surgeons. He collaborates with experts in surgery, radiation therapy, and radiology guides to accelerate the translation of new technologies into early clinical applications. Central to Dr. Siewerdsen’s research are issues of basic imaging physics, quantitative description of multi-dimensional imaging performance and imaging task, and the development of novel multidimensional imaging technologies.

Technology Portfolio• C11994: Information Source Mapping in Prior-Image-Based

Reconstruction • C11839: Tomographic Reconstruction Using Prior Images • C11523: Accurate Image Registration Method for Anatomy

Changes Between Scans • C11404: Novel Mathematical Model for CT Image

Reconstruction • C11019:Mountable “On-Board” Surgical Navigation and

Tracking System

Jeffrey H. Siewerdsen, Ph.D.Professor, Departments of Biomedical Engineering and Computer Science in the Russell H. Morgan Dept. of RadiologyFounder, I-STAR Lab

licensing AssociAteNestor FrancoLicensing AssociatePhone: 410-516-5654Email: [email protected]











Barbara Slusher, Ph.D. Director, Brain Science Institute NeuroTranslational Drug Discovery ProgramAssociate Professor, Department of Neurology

BiographyBarbara Slusher, Ph.D., is an associate professor of neurology and psychiatry and the director of the Brain Science Institute NeuroTranslational Drug Discovery Program at The Johns Hopkins University School of Medicine. She leads a 20-member veteran drug-discovery team consisting of medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetic/drug metabolism experts. The team is engaged in identifying novel drug targets identified at Johns Hopkins and translating them into new drug therapies for neurological and psychiatric disorders. Dr. Slusher cofounded “Cerecor”, a Baltimore-based biopharmaceutical company, to commercialize drug discovery projects from the BSi pipeline. Recently she co-developed the world’s largest global consortium for academic drug discovery scientists, the Academic Drug Discovery Consortium (ADDC), in an effort to coordinate and enhance the growing numbers of university-led drug discovery efforts. Dr. Slusher has more than 170 peer-reviewed manuscripts and published patents including several invited reviews, chapters and editorials.

Research InterestsDr. Slusher is regarded as an authority on CNS drug discovery and small molecule translational research. She is specifically interested in therapeutics that regulate glutamate neurotransmission including inhibitors of GCPII, xCT, glutaminase, and D-serine/D-amino acid oxidase.

Academic Drug Discovery ConsortiumThe Academic Drug Discovery Cosortium (ADDC) was created to connect the growing number of university-led drug discovery centers and programs around the world in order to accelerate the development of new therapeutics to enhance the lives of patients. The goal of the ADDC is to facilitate collaborations between various academic drug discovery centers allowing drug discovery scientists to exchange technical expertise related to drug development, including, but not limited to, drug screening platforms, medicinal chemistry data, technology transfer hurdles, steps toward patenting, and evolving strategies for effective partnership with pharmaceutical companies. Currently the consortium consists of 80 academic drug discovery centers/programs.

Technology Portfolio• C11717: High Throughput Method of Detecting D-Serine

in Plasma for Schizophrenia

licensing AssociAteHeather BakalyarPortfolio DirectorPhone: 410-516-6653 Email: [email protected]




BiographySaraswati Sukumar, Ph.D., is the Barbara B. Rubenstein Professor of Oncology and professor of pathology, and a preceptor in the human genetics and pathobiology graduate programs. She serves as the principal investigator of the DOD Center of Excellence, NCI’s Specialized Program of Research Excellence (SPORE) and of the AVON Breast Cancer Foundation. Dr. Sukumar has worked in the breast cancer field since her postdoctoral training at National Cancer Institute. She joined her first faculty position at the Salk Institute in La Jolla, CA in 1989, and then moved to the Johns Hopkins Oncology Center in 1994 as associate professor to assume the position of director of basic research at the newly formed breast cancer research program. She was promoted to professor in 2001. Dr. Sukumar has participated and chaired many grant review committees in the NIH, DOD, and Susan G Komen Foundation (SGKF). She is currently a scientific advisory board member of the SGKF for the Cure. In 2011, she received the BioMaryland LIFE Award.

Research InterestsDr. Sukumar’s laboratory is identifying gene alterations to study the consequences of these changes to the cellular machinery and to translate this knowledge to early detection and novel therapies for breast cancer. The lab has identified a large number of candidate oncogenes and tumor suppressor genes by SAGE and microarray analysis. Among these, they are currently analyzing tight junction proteins, Claudin-3, -4 and 7 and the homeotic genes, HOXA5 and HOXB7. HOXA5 is a potent transcriptional regulator of the progesterone receptor and the p53 gene, and its expression is lost in breast cancer cells. Few HOXA5 minus mice survive; the females have defects in lactation. HOXB7, on the other hand, is over expressed in breast cancer, and induces production of growth factors in cancer cells.

Technology Portfolio• C12014: A Highly Sensitive, Blood Based Test for

Methylation Detection in Cancer• C11625: Markers to Differentiate Between ER Subtypes,

Predict Treatment Outcome and Risk of Reoccurrence in Breast Cancer

• C11436: HOXB7 a Therapeutic Target for Drug Resistant Breast Cancer• C11063: PIK3CA Mutants Transgenic Mouse• C04936: HEYL, A Novel Oncogene• C04922: HOXB7 Inhibition to Prevent/Overcome Drug

Resistance in Breast Cancer

Saraswati Sukumar, Ph.D. Barbara B. Rubenstein Professorship in Oncology Professor of Pathology Codirector of the Breast Cancer Program at the Sidney Kimmel Comprehensive Cancer Center












Elaine Tierney, M.D.Associate Professor, Department of Psychiatry and Behavioral SciencesThe Johns Hopkins University School of MedicineDirector of Psychiatry, Kennedy Krieger Institute

BiographyElaine Tierney, M.D., received her BA from The University of Florida and her medical degree at The University of South Florida in 1989. After completing a transitional residency at Cook County Hospital in Chicago, IL and a general psychiatry residency at Johns Hopkins Hospital, she accepted a child and adolescent psychiatry fellowship at Johns Hopkins Hospital. She has served as the medical director of both Kennedy Krieger’s Neurobehavioral Unit and its Center for Autism and Related Disorders. She currently serves as director of psychiatry for Kennedy Krieger. Dr. Tierney is a pediatric and adult psychiatrist with a special interest in autism, genetic, metabolic and neurological disorders that cause behavioral disturbances.

Research InterestsDr. Tierney works with behavioral psychologists, neurologists, developmental pediatricians, nurses, communication specialists, educational specialists, social workers and occupational therapists to create treatments for individuals with ASD. Previously, her research had included the Research Units on Pediatric Psychopharmacology (RUPP) Multisite Project in autism, funded by the National Institute of Mental Health. The RUPP at Kennedy Krieger has completed double-blind, placebo-controlled studies of the use of risperidone and methylphenidate, and an open-blind study of the use of guanfacine in children and adolescents with ASD. Dr. Tierney directs the Autism Metabolic Research Program. This program, in coordination with the Kennedy Krieger Center for Genetic Disorders of Cognition and Behavior, investigates the presentation of ASD in individuals which have metabolic disorders (conditions in which chemical pathways in the body are not working properly). These conditions include mitochondrial disorders, Smith-Lemli-Opitz syndrome (SLOS) and other sterol disorders.

Dr. Tierney and colleagues at Kennedy Krieger, in collaboration with the National Institutes of Health and the Autism Genetic Resource Exchange have now begun analyzing the genes of the children with low cholesterol.

Technology Portfolio• C10705: Autism Spectrum Disorder: A Treatment

Approach

licensing AssociAteLaura MitchellLicensing AssociatePhone: 410-516-4969Email: [email protected]




BiographyPeter van Zijl, Ph.D., graduated cum laude with a master’s degree in inorganic chemistry and continued to obtain a doctoral degree in mathematics and physics. After completing fellowships in nuclear magnetic resonance (Carnegie Mellon University, Pittsburgh) and MRI (National Institutes of Health, National Cancer Institute), he became a research assistant professor at Georgetown University in 1990. In 1992, he was invited to join the department of radiology at The Johns Hopkins University School of Medicine, where he was promoted to associate professor (1992) and professor (1997). In 1999, he became the founding director of the F.M. Kirby Research Center for Functional Brain Imaging at the Kennedy Krieger Institute.

Research InterestsDr. van Zijl’s present research focuses on developing new methodologies for using MRI and Magnetic Resonance Spectroscopy (MRS) to study brain function and physiology. In addition he is working on understanding the basic mechanisms of the MRI signal changes measured during functional MRI (fMRI) tests of the brain. Other interests are in mapping the wiring of the brain (axonal connections between the brains functional regions) and the design of new technologies for molecular MRI such as imaging of proteins and peptides in tumors and tracking of cell migration and gene expression. A more recent interest is the development of bio-organic biodegradable MRI contrast agents. The ultimate goal is to transform these technologies into fast methods that are compatible with the time available for multi-modal clinical diagnosis using MRI.

Technology Portfolio• C11504: Improved MRI Technique to Evaluate Disease

Progression • C11306: Use of non-labeled Sugars in MRI • C10794: Magnetic Resonance Imaging and Spectroscopy

of low concentration solutes with exchangeable protons using Label Transfer Modules. Frequency Transfer, Inversion Transfer

• C04770: Non-invasive MRI Measurement of Tissue Glycogen • C04616: New Class of Reporter Genes for MRI Based on Chemical

Exchange Saturation Transfer (CEST) • C04457: The Use of Cerebralspinal Fluid as Inter-subject Normalization

Reference Standard for Magnetization Transfer Weighted Imaging • C03948: Magnetic Resonance Imaging and Spectroscopic Imaging of pH

Peter van Zijl, Ph.D.Director, F. M. Kirby Research Center, Kennedy Krieger Institute Research Scientist, Kennedy Krieger Institute Professor, Department of Radiology, The Johns Hopkins University School of Medicine

licensing AssociAteAmi GadhiaPortfolio DirectorPhone: 410-516-6515 Email: [email protected]















Ami GadhiaPortfolio DirectorPhone: 410-516-6515Email: [email protected]

licensing AssociAte

BiographyDr. Wahl joined The Johns Hopkins University faculty as director of the Division on Nuclear Medicine; director of the Positron Emission Tomography (PET) Center; and vice chair for technology and new business development within the Russell H. Morgan Department of Radiology and Radiological Sciences in 2000. Dr. Wahl is the principal editor of a best-selling imaging textbook, Principles and Practice of Positron Emission Tomography, and co-author of the Atlas of Clinical PET Imaging. He currently serves on the editorial boards of The Journal of Nuclear Medicine; Molecular Imaging and Biology; and Bioconjugates. He has authored more than 220 peer-reviewed manuscripts, has served on several NIH study sections and currently serves on the Medicare Technology Advisory Committee. He has been chairman of the American Board of Nuclear Medicine. Dr. Wahl has received multiple awards including the Berson and Yalow Award; Tetalman Award of the Society of Nuclear Medicine; The Hounsfield Award of the Society of Body CT; Academy of Molecular Imaging Distinguished Scientist Award, and has been honored as the New Horizons Lecturer for the Radiological Society of North America.

Research InterestsDr. Wahl’s primary research has included the diagnosis and treatment of cancer through the use of specifically targeted radiopharmaceuticals. Over the past 20 years, Dr. Wahl has been involved in the development of “smart radiopharmaceuticals”-targeting tumors for therapy and spare healthy tissue. He is a leading expert in PET, and was cited by the Academy of Molecular Imaging as the first person in the United States to apply PET technology to accurately diagnose a broad array of human cancers. Dr. Wahl was one of the first to develop radio-immunotherapy for the treatment of non-Hodgkin’s lymphoma. Dr. Wahl also pioneered computer methods that joined PET and CT technologies to form “fusion” images of cancer, and has been involved in the early stage evaluation of PET CT fusion technology,an increasingly routine procedure at Johns Hopkins.

Technology Portfolio• C11439: Personalized Disease Tracking Imaging System • C11130: An Automatic Method for the Determination of

Normal Reference Values in PET, SPECT, CT, MRI and other Molecular Imaging Studies

Richard Wahl, M.D., FACRProfessor of Radiology and Nuclear MedicineDirector, Division of Nuclear Medicine/PETVice Chair, Technology and New Business Development Russell H. Morgan Department of Radiology and Radiological Sciences






licensing AssociAte

Heather BakalyarPortfolio DirectorPhone: 410-516-6653 Email: [email protected]

Clifford Weiss, M.D. Assistant Professor, Radiology-Vascular and Interventional RadiologyClinical Director, Johns Hopkins Center for Bioengineering, Innovation and Design

Research InterestsDr. Weiss’ research foci include development and implementation of new MRI-guided interventions, the development of new interventional radiology techniques for use with cellular therapeutics, and development of new devices for interventional radiology. He has extensive grant funding from various societies, foundations, and corporations.

Technology Portfolio• C11892: Accessory for Reduction of Biofilm on Catheters• C11589: Implantable Three-way Diaphragm Valve• C11434: Hemodialysis port for increased longevity and

efficacy of access sites






Research InterestsDr. Wong’s laboratory is interested in understanding how various organs in the body coordinate the complex metabolic networks and circuitry to maintain proper energy balance. Specifically, his lab focuses on characterizing a novel family of endocrine mediators secreted by adipose tissue. Current projects seek to understand how these circulating factors regulate fat mass as well as systemic insulin sensitivity, glucose and lipid metabolism. These secreted factors, all belong to the C1q/TNF protein family, are related in structure and function to the insulin-sensitizing hormone, adiponectin. A variety of in vitro and in vivo (transgenic and knockout mice) approaches are being employed in his lab to dissect the function and mechanisms of action of these molecules.

Technology Portfolio• C12007: Protein Target for Treatment of Obesity and

Diabetes • C11853: Novel Protein Therapeutic for Diabetes and Obesity • C11446: Anti-Diabetic Actions of Novel Recombinant Protein

William Wong, Ph.D.Assistant Professor, Department of Physiology and Center for Metabolism and Obesity Research

licensing AssociAte

Jeffrey JamesLicensing AssociatePhone: 410-516-4560Email: [email protected]







licensing AssociAte

Aditi MartinLicensing AssociatePhone: 410-516-4566 Email: [email protected]

Srinivasan Yegnasubramanian, M.D., Ph.D.Assistant Professor of OncologyDirector, Next Generation Sequencing CenterSidney Kimmel Comprehensive Cancer Center The Johns Hopkins University School of Medicine

BiographySrinivasan Yegnasubramanian, M.D., Ph.D., is an assistant professor of oncology, and the director of the Next Generation Sequencing Center at the Sidney Kimmel Comprehensive Cancer Center in The Johns Hopkins University School of Medicine. He received his M.D. and Ph.D. at The Johns Hopkins University School of Medicine in 2006.

Research InterestsDr. Yegnasubramanian’s lab focuses on understanding the role of epigenetic alterations in establishing and driving neoplasia, and in exploiting this understanding to develop cancer biomarkers and therapeutic strategies. His lab has developed, refined, and/or implemented several approaches for global and high-resolution mapping of epigenetic DNA alterations in cancer genomes and for sensitive and specific detection of such alterations as cancer biomarkers. Dr. Yegnasubramanian and his team are currently developing epigenetic tests to help distinguish between indolent and aggressive prostate cancer in order to address this pressing clinical need and curb the over treatment of prostate cancer.

Technology Portfolio• C12051 and C12052: Castration Resistant Human Prostate

Cancer Cell Lines• C11663: 5hmC: A Novel Marker for Cancer Detection• C11598: Improved method for identification of DNA

methylation and biomarkers for prostate cancer detection• C11481: Novel Tissue Microarray for Standardized Cancer

Study• C05053: Small Molecules Epigenetic Inhibitors for Cancer

Prevention and Treatment• C04871: COMPARE-MS: A Novel Technique for Rapid,

Sensitive, And Accurate Detection of DNA Methylation












100 n. charles street, 5th floorBaltimore, M.d. 21201

410-516-8300www.techtransfer.jhu.edu

www.jhttonline.jhu.edu

images of vogelstein, kinde, and the neurology department were taken by keith weller commercial photography for Johns hopkins Medicine.

http://www.techtransfer.jhu.edu

http://www.jhttonline.jhu.edu

technology offerings: 2013 bio international convention

Documents

cancer genetics

genetics of human cancer

human cancer types

early diagnosis of cancer

variety of genetic mutations

genes responsible

coding genes

genes act